<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4731">
  <stage>Registered</stage>
  <submitdate>24/11/2014</submitdate>
  <approvaldate>24/11/2014</approvaldate>
  <nctid>NCT02309411</nctid>
  <trial_identification>
    <studytitle>EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis</studytitle>
    <scientifictitle>30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Young Children With Various Manifestations of Venous Thrombosis</scientifictitle>
    <utrn />
    <trialacronym>EINSTEINJr</trialacronym>
    <secondaryid>2014-000566-22</secondaryid>
    <secondaryid>14374</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous Thromboembolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rivaroxaban(Xarelto,BAY59-7939)

Experimental: Rivaroxaban - Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily


Treatment: drugs: Rivaroxaban(Xarelto,BAY59-7939)
With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of major bleeding and clinically relevant non-major bleeding</outcome>
      <timepoint>During or within 2 days after stop of study treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of recurrent symptomatic venous thromboembolisms</outcome>
      <timepoint>At 31 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Prothrombin time</outcome>
      <timepoint>Day1 (post dose at 2.5-4h),day 15 (post dose at 2-8h) and day 30 (post dose at 10-16h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Activated partial thromboplastin time</outcome>
      <timepoint>Day1 (post dose at 2.5-4h),day 15 (post dose at 2-8h) and day 30 (post dose at 10-16h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti-factor Xa activity - The anti-factor Xa assay is designed to measure plasma heparin,low molecular weight heparin and other anticoagulants</outcome>
      <timepoint>Day1 (post dose at 2.5-4h),day 15 (post dose at 2-8h) and day 30 (post dose at 10-16h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of asymptomatic deterioration in the thrombotic burden on repeat imaging</outcome>
      <timepoint>At 31 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Concentration of Rivaroxaban in blood as a measure of Pharmacokinetics</outcome>
      <timepoint>Day1 (post dose at.5-1.5h, 2.5-4h),day 15 (post dose at 2-8h) and day 30 (post dose at 10-16h)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Children aged 6 months to &lt; 6 years who have been treated for at least 2 months or, in
             case of catheter related thrombosis, for at least 6 weeks with LMWH (low molecular
             weight heparin), fondaparinux and/or VKA (vitamin K antagonist) for documented
             symptomatic or asymptomatic venous thrombosis - Hemoglobin, platelets, creatinine,
             alanine aminotransferase (ALT) and bilirubin evaluated within 10 days prior to
             randomization

          -  Informed consent provided</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>5</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active bleeding or high risk for bleeding contraindicating anticoagulant therapy

          -  Symptomatic progression of venous thrombosis during preceding anticoagulant treatment

          -  Planned invasive procedures, including lumbar puncture and removal of non peripherally
             placed central lines during study treatment

          -  An estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73 m2

          -  Hepatic disease which is associated with either: coagulopathy leading to a clinically
             relevant bleeding risk, or ALT&gt; 5x upper level of normal (ULN) or total bilirubin &gt; 2x
             ULN with direct bilirubin &gt; 20% of the total

          -  Platelet count &lt; 50 x 10*9/L

          -  Hypertension defined as &gt; 95th age percentile

          -  Life expectancy &lt; 3 months

          -  Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4)
             and P-glycoprotein (P-gp), i.e. all human immunodeficiency virus protease inhibitors
             and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole,
             posaconazole, if used systemically

          -  Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin,
             phenobarbital, phenytoin and carbamazepine

          -  Hypersensitivity or any other contraindication listed in the local labeling for the
             comparator treatment or experimental treatment

          -  Inability to cooperate with the study procedures

          -  Previous randomization to this study

          -  Participation in a study with an investigational drug or medical device within 30 days
             prior to randomization</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>15/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>47</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>5/04/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Parkville</hospital>
    <postcode>3052 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Auton. de Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Oberösterreich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Steiermark</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Tirol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles - Brussel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Minas Gerais</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>HUS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>TOULOUSE Cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen-Anhalt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig-Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Cork</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Afula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Veneto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kirov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnodar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhny Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Sankt-Peterburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Luzern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tyne and Wear</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Janssen Research &amp; Development, LLC</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find out whether rivaroxaban is safe to use in children and
      how long it stays in the body. Safety will be assessed by looking at the incidence and types
      of bleeding events. There will also be a check for worsening of blood clots.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02309411</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>